Tag: QUVIVIQ

All

Idorsia Reports Q1 2026 Results, Highlighting Pediatric Daridorexant Data and Expanding Clinical Evidence

The company’s first-quarter update emphasizes strong phase 2 results for daridorexant in children, ongoing real-world studies in patients with co-morbidities, and advancements in its sleep medicine pipeline.

Phase 2 Study Shows Daridorexant Improves Total Sleep Time in Pediatric Insomnia
Daridorexant Improves Sleep, Daytime Function in Menopausal-Age Women With Insomnia
Insomnia Drug Daridorexant Begins Phase 3 Study to Support South Korea Approval
Nxera Pharma Partners with Shionogi for Quviviq Distribution in Japan
Quviviq Approved for Insomnia Treatment in Japan
Daridorexant for Insomnia Nears Approval in Japan

All

The Unmet Need for New Insomnia Drugs

While DORAs offer a superior safety profile compared to Z-drugs, they fall short in terms of efficacy, leaving an unmet need for additional drug therapies with a superior efficacy and safety profile.

Swissmedic Approves QUVIVIQ to Treat Chronic Insomnia
Idorsia Insomnia Medication QUVIVIQ Now Covered by TRICARE
Insomnia Medication QUVIVIQ Receives FDA Approval

Tag: QUVIVIQ

All

Idorsia Reports Q1 2026 Results, Highlighting Pediatric Daridorexant Data and Expanding Clinical Evidence

Phase 2 Study Shows Daridorexant Improves Total Sleep Time in Pediatric Insomnia

Daridorexant Improves Sleep, Daytime Function in Menopausal-Age Women With Insomnia

Insomnia Drug Daridorexant Begins Phase 3 Study to Support South Korea Approval

Nxera Pharma Partners with Shionogi for Quviviq Distribution in Japan

Quviviq Approved for Insomnia Treatment in Japan

Daridorexant for Insomnia Nears Approval in Japan

All

The Unmet Need for New Insomnia Drugs

Swissmedic Approves QUVIVIQ to Treat Chronic Insomnia

Idorsia Insomnia Medication QUVIVIQ Now Covered by TRICARE

Insomnia Medication QUVIVIQ Receives FDA Approval

All

Sorry, No Posts Found

Sorry, No Posts Found

Sleep Review

Our Parent Company

Key Resources

Helpful Links